The skin landscape in diabetes mellitus. Focus on dermocosmetic management

Clinical, Cosmetic and Investigational Dermatology

Volumn 6, Issue , 2013, Pages 127-135

  Piérard, Gérald E ^a   Seité, Sophie ^b   Hermanns Lê, Trinh ^c   Delvenne, Philippe ^c   Scheen, André ^c   Piérard Franchimont, Claudine ^c  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b La Roche Posay Pharmaceutical Laboratories   (France)

^c UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Dermocosmetics; Diabetes mellitus; Diabetic xerosis; Skin

Indexed keywords

ADVANCED GLYCATION END PRODUCT; COLLAGEN TYPE 4;

ACANTHOSIS NIGRICANS; ALOPECIA AREATA; AUTOIMMUNITY; CALLUS; DIABETES MELLITUS; DIABETIC MICROANGIOPATHY; DISEASE ASSOCIATION; DRY SKIN; GRANULOMA ANNULARE; HUMAN; HYPERKERATOSIS; ICHTHYOSIS; INSULIN DEPENDENT DIABETES MELLITUS; LIPODYSTROPHY; MICROANGIOPATHY; NAIL DYSTROPHY; NECROBIOSIS LIPOIDICA; PIGMENTED PURPURIC DERMATOSIS; REVIEW; SCLERODERMA; SKIN CARE; SKIN DISEASE; VITILIGO; XEROSIS;

EID: 84877966391     PISSN: 11787015     EISSN: None     Source Type: Journal    
DOI: 10.2147/CCID.S43141     Document Type: Review

References (104)

1. Jelinek JE. The skin in diabetes. Diabetic Med. 1993;10(3):201-213.
2. Perez MI, Kohn SR. Cutaneous manifestations of diabetes mellitus. J Am Acad Dermatol. 1994;30(4):519-531.
3. Piérard-Franchimont C, Piérard GE, Lefèbvre P. Cutaneous manifestations of diabetes. Rev Med Liège. 1996;51(5):348-354. French.
4. Romano G, Moretti G, Di Benedetto A, et al. Skin lesions in diabetes mellitus: prevalence and clinical correlations. Diabetes Res Clin Pract. 1998;39(2):101-106.
5. Yosipovitch G, Hodak E, Vardi P, et al. The prevalence of cutaneous manifestations in IDDM patients and their association with diabetes risk factors and microvascular complications. Diabetes Care. 1998;21(4):506-509.
6. Flagothier C, Quatresooz P, Bourguignon R, Piérard-Franchimont C, Piérard GE. Cutaneous stigmata of diabetes mellitus. Rev Med Liège. 2005;60(5-6):553-559. French.
7. Kalus AA, Chien AJ, Olerud JE. Diabetes mellitus and other endocrine diseases. In: Goldsmith L, Katz S, Gilchrest B, Paller A, Leffell D, Wolff K, editors. Fitzpatrick's Dermatology in General Medicine, 8th ed. New York, NY: McGraw-Hill; 2012:151.
8. Diris N, Colomb M, Leymarie F, Durlach V, Caron J, Bernard P. Non infectious skin conditions associated with diabetes mellitus: a prospective study of 308 cases. Ann Dermatol Venereol. 2003; 130(11):1009-1014. French.
9. Nazratun N, Mahmood AA, Kuppusamy UR, Ahmad TS, Tan SY. Diabetes mellitus exacerbates advanced glycation end product accumulation in the veins of end-stage renal failure patients. Vasc Med. 2006;11(4):245-250.
10. Jack M, Wright D. Role of advanced glycation end products and glyoxalase I in diabetic peripheral sensory neuropathy. Transl Res. 2012;159(5):355-365.
11. Kang P, Tian C, Jia C. Association of RAGE gene polymorphisms with type 2 diabetes mellitus, diabetic retinopathy and diabetic nephropathy. Gene. 2012;500(1):1-9.
12. Noordzij MJ, Mulder DJ, Oomen PH, et al. Skin autofuorescence and risk of micro- and macrovascular complications in patients with Type 2 diabetes mellitus-a multi-centre study. Diabet Med. 2012;29(12): 1556-1561.
13. Perkins BA, Rabbani N, Weston A, et al. Serum levels of advanced glycation endproducts and other markers of protein damage in early diabetic nephropathy in type 1 diabetes. PLoS One. 2012;7(4):e35655.
14. Ramasamy R, Schmidt AM. Receptor for advanced glycation end products (RAGE) and implications for the pathophysiology of heart failure. Curr Heart Fail Rep. 2012;9(2):107-116.
15. Quatresooz P, Piérard GE. Immunohistochemical clues at aging of the skin microvascular unit. J Cutan Pathol. 2009;36(1):39-43.
16. Rendell M, Bamisedun O. Diabetic cutaneous microangiopathy. Am J Med. 1992;93(6):611-618.
17. Kolbe M, Kaufman JL, Friedman J, Dinerstein C, Mackenzie J W, Boyd CD. Changes in steady-state levels of mRNAs coding for type IV collagen, laminin and fbronectin following capillary basement membrane thickening in human adult onset diabetes. Connect Tissue Res. 1990;25(1):77-85.
18. Greives MR, Samra F, Pavlides SC, et al. Exogenous calreticulin improves diabetic wound healing. Wound Repair Regen. 2012;20(5): 715-730.
19. Pelizzo M, Zattra E, Nicolosi P, Peserico A, Garoli D, Alaibac M. In vitro evaluation of sunscreens: an update for the clinicians. ISRN Dermatol. 2012;2012:352135.
20. L'Alloret F, Candau D, Seité S, et al. New combination of ultraviolet absorbers in an oily emollient increases sunscreen effcacy and photostability. Dermatol Ther. 2012;2(1):4.
21. Uccioli L, Monticone G, Russo F, et al. Autonomic neuropathy and transcutaneous oxymetry in diabetic lower extremities. Diabetologia. 1994;37(10):1051-1055.
22. Gerrits EG, Lutgers HL, Kleefstra N, et al. Skin autofuorescence: a tool to identify type 2 diabetic patients at risk for developing microvascular complications. Diabetes Care. 2008;31(3):517-521.
23. Sell DR, Nelson JF, Monnier VM. Effect of chronic aminoguanidine treatment on age-related glycation, glycoxidation, and collagen cross-linking in the Fischer 344 rat. J Gerontol A Biol Sci Med Sci. 2001;56(9): B405-B411.
24. Pageon H, Técher M P, Asselineau D. Reconstructed skin modifed by glycation of the dermal equivalent as a model for skin aging and its potential use to evaluate anti-glycation molecules. Exp Gerontol. 2008;43(6):584-588.
25. Draelos ZD, Yatskayer M, Raab S, Oresajo C. An evaluation of the effect of a topical product containing C-xyloside and blueberry extract on the appearance of type II diabetic skin. J Cosmet Dermatol. 2009;8(2): 147-151.
26. Shemer A, Bergman R, Linn S, Kantor Y, Friedman-Birnbaum R. Diabetic dermopathy and internal complications in diabetes mellitus. Int J Dermatol. 1998;37(2):113-115.
27. Piérard GE, Arrese Estrada J, Piérard-Franchimont C, Deleixhe-Mauhin F. Is there a link between dendrocytes, fbrosis and sclerosis? Dermatologica. 1990;181(4):264-265.
28. Davison JE, Davies A, Moss C, Kirk JM, Taibjee SM, Agwu JC. Links between granuloma annulare, necrobiosis lipoidica diabeticorum and childhood diabetes: a matter of time? Pediatr Dermatol. 2010;27(2): 178-181.
29. Yosipovitch G, Loh KC, Hock OB. Medical pearl: Scleroderma-like skin changes in patients with diabetes mellitus. J Am Acad Dermatol. 2003;49(1):109-111.
30. Nikkels-Tassoudji N, Henry F, Letawe C, Piérard-Franchimont C, Lefebvre P, Piérard GE. Mechanical properties of the diabetic waxy skin. Dermatology. 1996;192(1):19-22.
31. Piérard-Franchmont C, Nikkels-Tassoudji N, Lefèbvre P, Piérard GE. Subclinical skin stiffening in adults suffering from type 1 diabetes mellitus. A comparison with Raynaud's syndrome. J Med Eng Technol. 1998;22(5):206-210.
32. Otto-Buczkowska E, Jarosz-Chobot P. Limited joint mobility syndrome in patients with diabetes. Int J Clin Pract. 2012;66(4):332-333.
33. Martin C, Requena L, Manrique K, Manzarbeltia FD, Rovira A. Scleredema diabeticorum in a patient with type 2 diabetes mellitus. Case Report Endocrinol. 2011;2011:560273.
34. Kroft EB, de Jong EM. Scleredema diabeticorum case series: successful treatment with UV-A1. Arch Dermatol. 2008;144(7):947-948.
35. Barde C, Masouyé I, Saurat JH, Le Gal FA. Scleroedema adultorum Buschke in a diabetic subject: intravenous immunoglobulin therapy. Ann Dermatol Venereol. 2009;136(4):360-363. French.
36. Lee FY, Chiu HY, Chiu HC. Treatment of acquired reactive perforating collagenosis with allopurinol incidentally improves scleredema diabeticorum. J Am Acad Dermatol. 2011;65(4):e115-e117.
37. Sehgal VN, Srivastava G, Aggarwal AK, Gupta M, Bhattacharya SN, Verma P. Noninsulin-dependent, type II diabetes mellitus-related dermatoses: part II. Skinmed. 2011;9(5):302-308.
38. El-Makki Ahmed M, Tamimi AO, Mahadi SI, Widatalla AH, Shawer MA. Hallux ulceration in diabetic patients. J Foot Ankle Surg. 2010;49(1):2-7.
39. Uhoda E, Debatisse B, Paquet P, Piérard-Franchimont C, Piérard GE. The so-called dry skin of the diabetic patient. Rev Med Liège. 2005; 60(5-6):560-563. French.
40. Piérard GE. What do you mean by dry skin? Dermatologica. 1989; 179(1):1-2.
41. Piérard GE, Goffin V, Hermanns-Lê T, Piérard-Franchimont C. Corneocyte desquamation. Int J Mol Med. 2000;6(2):217-221.
42. Sakai S, Kikuchi K, Satoh J, Tagami H, Inoue S. Functional properties of the stratum corneum in patients with diabetes mellitus: similarities to senile xerosis. Br J Dermatol. 2005;153(2):319-323.
43. Park HY, Kim JH, Jung M, et al. A long-standing hyperglycaemic condition impairs skin barrier by accelerating skin ageing process. Exp Dermatol. 2011;20(12):969-974.
44. Serup J. EEMCO guidance for the assessment of dry skin (xerosis) and ichthyosis: clinical scoring systems. Skin Res Technol. 1995;1(3): 109-114.
45. Piérard-Franchimont C, Petit L, Piérard GE. Skin surface patterns of xerotic legs: the fexural and accretive types. Int J Cosmet Sci. 2001; 23(2):121-126.
46. Piérard-Franchimong C, Quatresooz P, Piérard GE. Specular light refectance of fakes in seborrhoeic dermatitis of the scalp: a pilot study. Clin Exp Dermatol. 2011;36(7):793-796.
47. Seiraf H, Farsinejad K, Firooz A, et al. Biophysical characteristics of skin in diabetes: a controlled study. J Eur Acad Dermatol Venereol. 2009;23(2):146-149.
48. Piérard-Franchimont C, Piérard GE. Beyond a glimpse at seasonal dry skin: a review. Exog Dermatol. 2002;1(1):3-6.
49. Mac-Mary S, Sainthillier JM, Humbert P. Dry skin and the environment. Exog Dermatol. 2004;3(1):72-80.
50. Piérard GE, Piérard-Franchimont C, Scheen A. Critical assessment of diabetic xerosis. Expert Opin Med Diag. 2013;7(2):201-207.
51. Pirot F, Morel B, Peyrot G, et al. Effects of osmosis on water-holding capacity of stratum corneum and skin hydration. Exog Dermatol. 2003;2(1):252-257.
52. Pirot F, Falson F, Pailler-Mattéi C, Maibach HI. Stratum corneum: an ideal osmometer? Exog Dermatol. 2004;3(6):339-349.
53. Berardesca E; European Expert Group for Effcacy Measurements on Cosmetics and Other Topical Products (EEMCO). EEMCO guidance for the assessment of stratum corneum hydration: electric methods. Skin Res Technol. 1997;3(2):126-132.
54. Fischer T W, Wigger-Alberti W, Elsner P. Assessment of "dry skin": current bioengineering methods and test designs. Skin Pharmacol Appl Skin Physiol. 2001;14(4):183-195.
55. Lee CM, Maibach HI. Bioengineering analysis of water hydration: an overview. Exog Dermatol. 2002;1(1):269-275.
56. O'goshi K, Serup J. Inter-instrumental variation of skin capacitance measured with the Corneometer. Skin Res Technol. 2005;11(2):107-109.
57. Lévêque JL, Xhaufaire-Uhoda E, Piéard GE. Skin capacitance imaging, a new technique for investigating skin surface properties. Eur J Dermatol. 2006;16(5):500-506.
58. Xhaufaire-Uhoda E, Piérard GE, Quatresooz P. The skin landscape following nonoptical capacitance imaging. Am J Clin Dermatol. 2010;11(2):89-94.
59. Piérard-Franchimont C, Piérard GE. Skin surface stripping in diagnosing and monitoring infammatory, xerotic, and neoplastic diseases. Pediatr Dermatol. 1985;2(3):180-184.
60. Piérard-Franchimont C, Piérard GE. Assessment of aging and actinic damages by cyanoacrylate skin surface strippings. Am J Dermatopathol. 1987;9(6):500-509.
61. Piérard GE, Piérard-Franchimont C, Saint-Léger D, Kligman AM. Squamometry: the assessment of xerosis by colorimetry of D-squame adhesive discs. J Soc Cosmet Chem. 1992;47:297-305.
62. Piérard GE. EEMCO guidance for the assessment of dry skin (xerosis) and ichthyosis: evaluation by stratum corneum strippings. Skin Res Technol. 1996;2(1):3-11.
63. Piérard-Franchimont C, Henry F, Piérard GE. The SACD method and the XLRS squamometry tests revisited. Int J Cosmet Sci. 2000;22(6): 437-446.
64. Yoon HS, Baik SH, Oh CH. Quantitative measurement of desquamation and skin elasticity in diabetic patients. Skin Res Technol. 2002;8(4): 250-254.
65. Schatz H, Altmeyer PJ, Kligman A. Dry skin and scaling evaluated by D-squames and image analysis. In: Serup J, Jemec GBE, Grove GL, editors. Handbook of Non-Invasive Methods and the Skin, 2nd ed. Boca Raton, FA: CRC Press; 2006:375-379.
66. Takahashi M, Black D, Hughes B, Marks R. Exploration of a quantitative dansyl chloride technique for measurement of the rate of desquamation. Clin Exp Dermatol. 1987;12(4):246-249.
67. Piérard GE. Microscopic evaluation of dansyl chloride test. Dermatology. 1992;185(1):37-40.
68. Paye M, Simion FA, Piérard GE. Dansyl chloride labelling of stratum corneum: its rapid extraction from skin predict skin irritation due to surfactants and cleansing products. Contact Dermatitis. 1994;30(2): 91-96.
69. Piérard GE, Piérard-Franchimont C. Dihydroxyacetone test as a substitute for the dansyl chloride test. Dermatology. 1993;186(2): 133-137.
70. Uhoda E, Piérard-Franchimont C, Debatisse B, Wang X, Piérard GE. Repair kinetics of stratum corneum under repeated insults. Exog Dermatol. 2004;3(1):7-11.
71. Pavicic T, Korting HC. Xerosis and callus formation as a key to the diabetic foot syndrome: dermatologic view of the problem and its management. J Dtsch Dermatol Ges. 2006;4(11):935-941.
72. Pham HT, Exelbert L, Segal-Owens A, Veves A. A prospective, randomized, controlled double-blind study of a moisturizer for xerosis of the feet in patients with diabetes. Ostomy Wound Manage. 2002;48(5): 30-36.
73. Lodén M. Role of topical emollients and moisturizers in the treatment of dry skin barrier disorders. Am J Clin Dermatol. 2003;4(11):771-788.
74. Lodén M. The clinical beneft of moisturizers. J Eur Acad Dermatol Venereol. 2005;19(6):672-688.
75. Xhaufaire-Uhoda E, Fontaine K, Piérard GE. Kinetics of moisturizing and frming effects of cosmetic formulations. Int J Cosmet Sci. 2008;30(2):131-138.
76. Ananthapadmanabhan K P, Yang L, Vincent C, et al. A novel technology in mild and moisturizing cleansing liquids. Cosmet Dermatol. 2009; 22(6):307-316.
77. Quatresooz P, Piérard-Franchimont C, Szepetiuk G, Devillers C, Piérard GE. Fungal chitin-glucan scaffold for managing diabetic xerosis of the feet in menopausal women. Expert Opin Pharmacother. 2009;10(14):2221-2229.
78. Shi V Y, Tran K, Lio PA. A comparison of physicochemical properties of a selection of modern moisturizers: hydrophilic index and pH. J Drugs Dermatol. 2012;11(5):633-636.
79. Seité S, Khemis A, Rougier A, Ortonne J P. Importance of treatment of skin xerosis in diabetes. J Eur Acad Dermatol Venereol. 2011;25(5): 607-609.
80. Hermanns-Lê T, Hermanns JF, Piérard GE. Juvenile acanthosis nigricans and insulin resistance. Pediatr Dermatol. 2002;19(1):12-14.
81. Hermanns-Lê T, Scheen A, Piérard GE. Acanthosis nigricans associated with insulin resistance; pathophysiology and management. Am J Clin Dermatol. 2004;5(3):199-203.
82. Romo A, Benavides S. Treatment options in insulin resistance obesity-related acanthosis nigricans. Ann Pharmacother. 2008;42(7): 1090-1094.
83. Piérard-Franchimont C, Jebali A, Ezzine N, Letawe C, Piérard GE. Seasonal variations in polymorphis nail surface changes associated with diabetes mellitus. J Eur Acad Dermatol Venereol. 1996;7(2):182-196.
84. Piérard GE, Piérard-Franchimont C. The nail under fungal siege in patients with type II diabetes mellitus. Mycoses. 2005;48(5):339-342.
85. Piérard GE, Piérard-Franchimont C, Marks R, Elsner P; EEMCO Group (European Expert Group on Effcacy Measurement of Cosmetics and Other Topical Products). EEMCO guidance for the assessment of hair shedding and alopecia. Skin Pharmacol Physiol. 2004;17(2):98-110.
86. Goodman JI. Diabetic anhidrosis. Am J Med. 1966;41(5):831-835.
87. Kennedy WR, Sakuta M, Sutherland D, Goetz FC. Quantifcation of the sweating defcit in diabetes mellitus. Ann Neurol. 1984;15(5): 482-488.
88. Fealey RD, Low PA, Thomas JE. Thermoregulatory sweating abnormalities in diabetes mellitus. Mayo Clinic Proc. 1989;64(6):617-628.
89. Piérard GE, Elsner P, Marks R, Masson P, Paye M; EEMCO group. EEMCO guidance for the effcacy assessment of antiperspirants and deodorants. Skin Pharmacol Appl Skin Physiol. 2003;16(5): 324-342.
90. Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. Diabetes Care. 2003;26(5):1553-1579.
91. Petrofsky JS, Lee S, Patterson C, Cole M, Stewart B. Sweat production during global heating and during isometric exercise in people with diabetes. Med Sci Monit. 2005;11(11):CR515-CR521.
92. Philips JC, Marchand M, Scheen AJ. Pulse pressure and cardiovascular autonomic neuropathy according to duration of type 1 diabetes. Diabetes Metab Res Rev. 2009;25(5):442-451.
93. Provitera V, Nolano M, Caporaso G, Stancanelli A, Santoro L, Kennedy WR. Evaluation of sudomotor function in diabetes using the dynamic sweat test. Neurology. 2010;74(1):50-56.
94. Xhaufaire-Uhoda E, Mayeux G, Quatresooz P, Scheen A, Piérard GE. Facing up to the imperceptible perspiration. Modulation infuences by diabetic neuropathy, physical exercise and antiperspirant. Skin Res Technol. 2011;17(4):487-493.
95. Noël F, Piérard-Franchimont C, Piérard GE, Quatresooz P. Sweaty skin, background and assessments. Int J Dermatol. 2012;51(6):647-655.
96. Caucanas M, Piérard-Franchimont C, Piérard GE. Pruritus, a frequent worry. Rev Med Liège. 2010;65(10):593-597. French.
97. Rurangirwa A, Piérard-Franchimont C, Piérard GE. Growth of Candida albicans on the stratum corneum of diabetic and non-diabetic patients. Mycoses. 1990;33(5):253-255.
98. Quatresooz P, Paquet P, Hermanns-Lê T, Piérard GE. Molecular mapping of Factor XIIIa-enriched dendrocytes in the skin (Review). Int J Mol Med. 2008;22(4):403-409.
99. Kumar K V, Priya S, Shaikh A, Prusty P. Diabetes in young - unusual case presentation. J Pediatr Endocrinol Metab. 2011;24(7-8):581-583.
100. Nakatani K, Kurose T, Hyo T, et al. Drug-induced generalized skin eruption in a diabetes mellitus patient receiving a dipeptidyl peptidase-4 inhibitor plus metformin. Diabetes Ther. 2012;3(1):14.
101. Piérard-Franchimont C, Hermanns-Lê T, Scheen AJ, Piérard GE. Cutaneous complications of insulin therapy. A drug-induced condition on the decline. Rev Med Liège. 2005;60(5-6):564-565. French.
102. Radermecker R P, Piérard GE, Scheen AJ. Lipodystrophy reactions to insulin: effects of continuous insulin infusion and new insulin analogs. Am J Clin Dermatol. 2007;8(1):21-28.
103. Lind PM, Zethelius B, Lind L. Circulating levels of phthalate metabolites are associated with prevalent diabetes in the elderly. Diabetes Care. 2012;35(7):1519-1524.
104. Drab SR. Recognizing the rising impact of diabetes in seniors and implications for its management. Consult Pharm. 2009;24 Suppl B: S5-S10.